Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.
Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.
The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.
Tissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression on frontline atezolizumab and bevacizumab to targeted therapy or another TKI based on identified genomic alterations.
Neoadjuvant treatment with the combination of nivolumab and ipilimumab led to responses and was well tolerated in patients with resectable hepatocellular carcinoma.